Okomera

Just arrived at Servier R&D Partnering day. Don't hesitate to ping me if you are around

🌟 I am super proud to announce from the Big 2024 Bpifrance conference - during the opening speech of Yasmine Belkaid, the CEO of Pasteur Institute - that Okomera is selected in the Excellence Club of the French Public Bank Bpifrance among other leading techbio like AQEMIA ! 2,000 Companies only selected nationally in France that the French Public bank is committed to help get to the next level : 🤝 Boost Business: Targeted networking with inspiring personalities. 📈 Priority Support: Tailored guidance from Bpifrance’s Exec Team. 🧠 Inspiration: Exclusive access to Bpifrance Le Lab and expert events. 🌐 Networking: Invitations to unique gatherings and events in your region I want to thank Corentin Molson for his tremendous support, Flora Vignjevic, Julie Lellouche along the way - and Bpifrance showcasing that drug development is a priority topic for France ! After being Laureate of i-lab in 2019 and i-nov in 2023, this new award is again a sign of the support of public institutions for our fight against cancer ! Let's go!

🇫🇷🏭Reindustrializing France : is this a dream ? Yesterday I had the chance to meet Herve de Malliard the dynamic CEO of MGA Tech, a French Lifescience Manufacturer working for leading names like Sanofi and was captivated by his enthusiasm for the French Industry. 🛠️His dream ? Boosting Made in France, and that's why he cofounded the French Fab label. 🏆Quick numbers : Industry represents 12.3% of the French GDP, includes 260,000 companies (90% of which are SMEs) and accounts for 3.11 million direct jobs As BPI Big 2024 is starting tomorrow and as an engineer myself I was reboosted by the enthusiasm of such firm believers of an industry in France ! Thank you Stephane Buttin Sébastien Bernay for the great visit - let's get to work!

Nobel Prize in Medicine 2024 awarded to 2 American Scientists - Victor Ambros and Gary Ruvkun - for their groundbreaking discovery of microRNA, a small but crucial molecule that plays a key role in regulating gene activity post-transcription. This discovery revealed a whole new layer of gene regulation that fine-tunes how proteins are produced in our cells, impacting everything from development to disease prevention 🔬 Discovery Highlights: Their work on C. elegans uncovered microRNAs, which regulate genes by binding to complementary mRNA sequences, blocking protein production. This innovative mechanism is now known to be essential for the function and development of all multicellular organisms, including humans. Their Key Publications to read : 1. Lee RC, Feinbaum RL, Ambros V. (1993). The C. elegans gene lin-4 encodes small RNAs that complement lin-14, revealing a new RNA-based mechanism of gene regulation. Cell, 75(5), 843-854. doi:10.1016/0092-8674(93)90529-y 2. Wightman B, Ha I, Ruvkun G. (1993). lin-4 regulates the timing of gene expression in C. elegans by controlling lin-14 protein production at a post-transcriptional level. Cell, 75(5), 855-862. doi:10.1016/0092-8674(93)90530-4 3. Pasquinelli AE et al. (2000). The let-7 microRNA is highly conserved across species, regulating developmental timing from C. elegans to humans. Nature, 408(6808), 86-89. doi:10.1038/35040556

🌟 Super proud to announce that Okomera is selected in the Excellence Club of the French Public Bank Bpifrance among other leading techbio like AQEMIA ! 2,000 Companies only selected nationally in France that the French Public bank is committed to help get to the next level : 🤝 Boost Business: Targeted networking with inspiring personalities. 📈 Priority Support: Tailored guidance from Bpifrance’s Exec Team. 🧠 Inspiration: Exclusive access to Bpifrance Le Lab and expert events. 🌐 Networking: Invitations to unique gatherings and events in your region I want to thank Corentin Molson for his tremendous support, Flora Vignjevic, Julie Lellouche along the way - and Bpifrance showcasing that drug development is a priority topic for France ! After being Laureate of i-lab in 2019 and i-nov in 2023, this new award is again a sign of the support of public institutions for our fight against cancer ! Let's go!

⚡Okomera at ELRIG Drug Discovery 2024 in London! Exciting insights into the future of automation and high-throughput screening! 🤖 Leading Big Pharma like Boehringer Ingelheim shared cutting-edge examples of scaling up assays with robotics to screen millions of compounds in record time—game-changing for drug discovery! 🧫We’re also seeing a surge in interest for organoid-on-chip technology, showcased by both academic and life science institutions, cementing its role in the discovery workflow Special feature of my friend Etienne Croquette from UK Robotics!

Excited to be back in London 🇬🇧 this week for ELRIG Drug Discovery 2024 ! Don't hesitate to ping me if you want to meet at the conference

Join us today 12.30 PM New York time, 6.30 PM Paris time for an exciting talk for IBM Z Day. Happy to share how we are using data security as a competitive advantage for oncology drug discovery and precision medicine pipeline with our users. Hear from my co-panelists Ryan Young, MD, MBA Quimby Melton and Patricia Thaine Register here : https://lnkd.in/gc6WHEVf Thank you Adam LG R. for the great opportunity !

Kicking the visit of our 🇸🇪 Swedish biotech partner Neogap, spin off from Karolinksa work in our Paris office with a stylish dinner ! We are so excited to host Hans Grönlund, PI Therapeutic immune design, at Karolinska and Founder / CSO of Neogap - visiting along with his team Inspiring to work with leading KOLs from France, UK, US and Sweden at Okomera ! 🧬 Efficient T-cell Analysis: We develop an efficient analysis of how T-cells interact with and kill tumor cells, requiring only minimal samples. 🔬 Measuring Therapy Potency: The goal is to assess the effectiveness of Neogap's pTTL therapy by evaluating its tumor-killing capabilities. 🎯 Predicting Treatment Success: This collaboration aims to develop reliable methods for predicting the success of personalized T-cell therapies in cancer treatment.

Patient Derived Organoids in esophago-gastric adenocarcinoma (EGC) to stratify patient response to FLOT chemotherapy - very interesting study done in Dresden, Germany 🇩🇪 🧪PDOs were cultured from biopsies of 120 EGC patients and tested in vitro against FLOT components. The PDO responses showed strong alignment with patient outcomes, especially with 5-FU and the full FLOT regimen, confirming their value for response prediction. 📊High Diagnostic Precision for FLOT A PDO-based response threshold was established, showing excellent accuracy in classifying FLOT responders. In an exploratory cohort of 13 patients, the model achieved 90% sensitivity, 100% specificity, and 92% accuracy. The ROC analysis delivered an impressive AUC of 0.994, indicating high predictive precision for FLOT efficacy. Credit : Schmäche, Tim, et al. ‘Stratifying Esophago-Gastric Cancer Treatment Using a Patient-Derived Organoid-Based Threshold’. Molecular Cancer, vol. 23, no. 1, Jan. 2024, p. 10. Springer Link, https://lnkd.in/gq_by_iH